Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Barbiturates

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28 result(s) found for: Barbiturates. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2010-023311-34 Sponsor Protocol Number: CPA 368-10 Start Date*: 2011-02-04
    Sponsor Name:AOP Orphan Pharmaceuticals AG
    Full Title: A prospective, randomized, double blinded, crossover, two-treatment, two-sequence, short term pharmacokinetic, pharmacodynamic and tolerability, single centre study to compare AOP200704 vs. Esmolol...
    Medical condition: healthy male and female volunteers, intended for the treatment of dobutamine-induced tachycardia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10040752 Sinus tachycardia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2007-006236-63 Sponsor Protocol Number: EVT 302/3011 Start Date*: 2008-01-23
    Sponsor Name:Evotec Neurosciences GmbH
    Full Title: A double-blind, randomized, placebo- and NRT-controlled Phase II study to assess the effects of EVT 302 alone and in combination with NRT on craving and withdrawal in healthy male smokers deprived ...
    Medical condition: Smoking cessation. Assessment of the effect of EVT 302 alone or in combination with a nicotine replacement therapy (NRT) on craving and withdrawal in smokers after short-term deprivation of cigare...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10053325 Smoking cessation therapy LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001535-21 Sponsor Protocol Number: RG101-02 Start Date*: 2015-07-14
    Sponsor Name:Regulus Therapeutics Inc.
    Full Title: A Randomized, Multi-Center, Phase 2 Study to Evaluate Safety and Efficacy of Subcutaneous Injections of RG-101 in Combination with Oral Agents in Treatment Naïve, Genotype 1 and 4, Chronic Hepatiti...
    Medical condition: Treatment Naïve, Genotype 1 and 4, Chronic Hepatitis C Patients
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004848 10076315 Hepatitis C virus genotype 4 positive LLT
    18.0 100000004862 10074391 Chronic hepatitis C virus genotype 1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021044-17 Sponsor Protocol Number: CLOCK_depression Start Date*: 2010-08-11
    Sponsor Name:Medizinische Universität Wien
    Full Title: The effect of agomelatine on CLOCK gene expression in patients with major depressive disorder and healthy controls: an exploratory study.
    Medical condition: Major depressive disorder (MDD), Seasonal affective disorder (subtype of MDD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012378 Depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017800-10 Sponsor Protocol Number: CZB/4/722 Start Date*: 2010-04-01
    Sponsor Name:NHS Lothian [...]
    1. NHS Lothian
    2. University of Edinburgh
    Full Title: Scottish and Newcastle Anti-emetic Pre-treatment for Paracetamol Poisoning study (SNAP)
    Medical condition: Paracetamol overdose
    Disease: Version SOC Term Classification Code Term Level
    2.2 10033295 Overdose LLT
    2.2 10033297 accidental overdose LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-003307-13 Sponsor Protocol Number: 07-001 Start Date*: 2008-01-28
    Sponsor Name:Jazz Pharmaceuticals, Inc.
    Full Title: A Phase 2a, Open-label, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intranasal Clonazepam in Adult Subjects with Epileptic Seizures
    Medical condition: Recurrent Acute Repetitive Seizures (ARS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039910 Seizures LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000271-39 Sponsor Protocol Number: 2022-01 Start Date*: 2022-09-02
    Sponsor Name:Adeptio Pharmaceuticals Ltd
    Full Title: Single-arm, open-label dose titration phase 2 clinical trial of (+)-α-DHTBZ for the treatment of tardive dyskinesia (TD)
    Medical condition: Tardive dyskinesia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10043118 Tardive dyskinesia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002181-32 Sponsor Protocol Number: RG012-03 Start Date*: 2016-12-07
    Sponsor Name:Regulus Therapeutics Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Dose Selection, and Preliminary Efficacy of Weekly RG 012 Injections in Pat...
    Medical condition: Alport syndrome is an inherited form of kidney disease caused by mutations in genes coding for the capillary basement membrane collagen IV
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006694-39 Sponsor Protocol Number: ASF-CP02-001 Start Date*: 2022-07-08
    Sponsor Name:Lantmännen Medical AB
    Full Title: An open-label, historical cohort control study to evaluate the safety and tolerability of AF-16 in patients with cerebral oedema caused by traumatic brain injury (TBI)
    Medical condition: Cerebral oedema caused by traumatic brain injury (TBI)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004863 10060690 Traumatic brain injury LLT
    20.1 100000004852 10008127 Cerebral oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004394-10 Sponsor Protocol Number: ACT16248 Start Date*: 2020-06-30
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of Lademirsen (SAR339375) for Subcutaneous Injection Administe...
    Medical condition: Congenital, hereditary and neonatal diseases
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10001843 Alport's syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001306-41 Sponsor Protocol Number: ALD403-CLIN-011 Start Date*: 2017-04-27
    Sponsor Name:Alder BioPharmaceuticals, Inc.
    Full Title: A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients with Chronic Migraine
    Medical condition: Chronic Migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) DK (Completed) DE (Completed) BE (Completed) SK (Completed) HU (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002653-35 Sponsor Protocol Number: R668-AD-1424 Start Date*: 2016-01-14
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A phase 3 study investigating the efficacy, safety, and tolerability of Dupilumab administered to adult patients with severe atopic dermatitis who are not adequately controlled with or are intolera...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) BE (Completed) GB (Completed) NL (Completed) SK (Completed) AT (Completed) IE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-001122-13 Sponsor Protocol Number: BP21850 Start Date*: 2009-05-08
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Multi-center, randomized, double-blind, 5-arm parallel group, placebo controlled 4 week study to investigate the safety, tolerability and efficacy of two doses each (near to maximum tolerated dose ...
    Medical condition: Type 2 Diabetes (T2D)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002929-78 Sponsor Protocol Number: CARISEPY3007- Amendment INT-2/GBR-1 Start Date*: 2007-11-13
    Sponsor Name:Ortho-McNeil Janssen Scientific Affairs, LLC
    Full Title: A Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Retention Rate, Efficacy, Safety, and Tolerability of Carisbamate, Topiramate and Levetiracetam as Adjunctive Therapy i...
    Medical condition: Partial onset seizures
    Disease: Version SOC Term Classification Code Term Level
    9.1 10034091 Partial seizures, simple LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) CZ (Prematurely Ended) BE (Temporarily Halted) FI (Completed) FR (Completed) IT (Prematurely Ended) ES (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002967-23 Sponsor Protocol Number: M-17923-30 Start Date*: 2022-01-27
    Sponsor Name:Almirall, S.A.
    Full Title: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adult and Adolescent Patients ...
    Medical condition: atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Ongoing) FR (Ongoing) ES (Ongoing) PL (Ongoing) BE (Completed) IT (Ongoing) NL (Completed) AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005510-34 Sponsor Protocol Number: MMV_DSM265_14_01 Start Date*: 2015-09-30
    Sponsor Name:Medicines for Malaria Venture
    Full Title: Evaluation of the prophylactic antimalarial activity of a single dose of DSM265 in non-immune healthy adult volunteers by controlled human malaria infection with PfSPZ Challenge
    Medical condition: Healthy volunteers; controlled human malaria infection with PfSPZ
    Disease: Version SOC Term Classification Code Term Level
    18.1 10042613 - Surgical and medical procedures 10025494 Malaria prophylaxis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007687-41 Sponsor Protocol Number: CARISEPY3013 Start Date*: 2009-02-17
    Sponsor Name:Janssen Cilag International, NV
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial On...
    Medical condition: Epilepsy with partial onset seizures
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015037 Epilepsy LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: View results
    EudraCT Number: 2009-014269-25 Sponsor Protocol Number: A0081096 Start Date*: 2009-12-18
    Sponsor Name:Pfizer Inc
    Full Title: PROSPECTIVE RANDOMIZED 12-WEEK CONTROLLED STUDY OF VISUAL FIELD CHANGE IN SUBJECTS WITH PARTIAL SEIZURES RECEIVING PREGABALIN OR PLACEBO
    Medical condition: EPILEPSY WITH PARTIAL SEIZURE
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004852 10065336 Partial epilepsy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-002178-22 Sponsor Protocol Number: 11-AVR-130 Start Date*: 2011-12-26
    Sponsor Name:Avanir Pharmaceuticals, Inc.
    Full Title: A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in ...
    Medical condition: Central Neuropathic Pain in Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-004409-34 Sponsor Protocol Number: ESN364-PCO-201 Start Date*: 2015-01-21
    Sponsor Name:Ogeda S.A
    Full Title: Phase IIa, Double-Blind, Placebo-Controlled, Study of ESN364 Administered for 12 Weeks to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Women Presenting With Po...
    Medical condition: Polycystic Ovarian Syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004872 10065161 Polycystic ovarian syndrome LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) AT (Completed) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 22:09:27 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA